Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Metagenomi, Inc. ( (MGX) ) is now available.
On January 12, 2026, Metagenomi Therapeutics, Inc. formally changed its corporate name from Metagenomi, Inc. and updated its charter and bylaws accordingly, while retaining its Nasdaq listing under the ticker MGX and its existing CUSIP, signaling a strategic emphasis on its therapeutic focus rather than any change to shareholder rights or capital structure. In a related January 12, 2025 announcement, the company highlighted 2025 preclinical milestones for MGX-001, including curative and durable FVIII activity with no identifiable off-target editing in non-human primates and a completed pre-IND meeting in the fourth quarter of 2025, as well as progress in secreted protein deficiency and cardiometabolic programs, all under a pipeline reprioritization and revised capital allocation plan that extends its projected cash runway through the fourth quarter of 2027 and positions it for potential regulatory submissions in late 2026 and a first-in-human study of MGX-001 in 2027.
The most recent analyst rating on (MGX) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Metagenomi, Inc. stock, see the MGX Stock Forecast page.
Spark’s Take on MGX Stock
According to Spark, TipRanks’ AI Analyst, MGX is a Neutral.
Metagenomi, Inc. faces significant challenges with profitability and cash flow, reflected in a low valuation score. Technical indicators suggest bearish momentum. However, recent corporate events show strategic initiatives that could improve long-term prospects.
To see Spark’s full report on MGX stock, click here.
More about Metagenomi, Inc.
Metagenomi Therapeutics, Inc. is an in vivo genome editing company developing curative genetic medicines based on proprietary metagenomics-derived editing tools designed to correct a wide range of genetic mutations. The company’s lead wholly owned program, MGX-001 for hemophilia A, aims to provide one-time, durable genome editing to deliver lifelong protection from bleeding events, while its broader pipeline targets additional secreted protein deficiencies using the MGX-001 integration system and partnered cardiometabolic indications through a collaboration with Ionis Pharmaceuticals.
Average Trading Volume: 516,582
Technical Sentiment Signal: Sell
Current Market Cap: $66.46M
See more data about MGX stock on TipRanks’ Stock Analysis page.